October 11, 2017 05:04 PM EDTUpdated October 12, 10:21 AM
R&D

Pos­i­tive PhI­II can't sal­vage Mer­ck­'s anace­trapib, now rel­e­gat­ed to the scrap heap

John Carroll

Editor & Founder

There will be no CETP heart drug mir­a­cle in the works at Mer­ck.

The phar­ma gi­ant looked over a set of pos­i­tive but trou­ble­some Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times